Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Dyadic International, Inc.NASDAQ: DYAI

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 36.4M shares rose 21.8% year over year, ahead of the +13.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 11.6% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.8% holds above the trailing-twelve-month pace of +13.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
36.4M+11.6% QoQ
Last fiscal yearDec 2025
32.62M+11.3% YoY
LTMMar 2026
33.41M+13.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.8%——
1 year+11.3%——
3-year CAGR+4.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
32.62M USD
Year-over-year change
+11.3%
4-year CAGR
+4.0%

Weighted Avg Shares (Diluted) vs competitors

How DYAI compares with its peers on the latest reported figures

  • DYAI's LTM Mar 2026 weighted avg shares (diluted) of 33.41M shares is the 2nd highest of the 8 companies compared; the peer median is 22.96M shares.
  • Its year-over-year change of +13.2% is the lowest of 8, against a peer median of +42.8%.
  • Over three fiscal years its annual growth of +4.8% compares with a peer median of +36.0%.
DYAI Competitors Peer median
Weighted Avg Shares (Diluted) for DYAI and competitors
Company Period LTM YoY 3-year CAGR
RNXTRenovoRx, Inc.LTM Mar 202636.65M +42.8%+25.0%
DYAIDyadic International, Inc.LTM Mar 202633.41M +13.2%+4.8%
MAIAMAIA Biotechnology, Inc.LTM Mar 202631.93M +27.8%+51.3%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+19.5%
ANVSAnnovis Bio, Inc.LTM Mar 202622.96M +82.5%+36.0%
PYPDPolyPid Ltd.LTM Mar 202618.85M +145.8%+132.9%
VERUVeru Inc.LTM Mar 202617.82M +21.7%+22.3%
ATHEAlterity Therapeutics LimitedFY202510.66M +75.3%+38.5%
Peer median (excluding DYAI) 22.96M+42.8%+36.0%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.